Lantheus’ shares rose 8.0% following a quarter marked by better-than-expected commercial execution and meaningful regulatory progress, supporting confidence in the company’s focused radio diagnostics strategy and growth trajectory.

• PYLARIFY U.S. volumes grew approximately 5.8% year-over-year, holding stable net ASPs despite competitive pressures.
• FDA approval of PYLARIFY TRUVU, a manufacturing-optimized formulation, positions Lantheus to increase supply and geographic reach starting in Q4.
• Positive regulatory developments include tentative FDA approval for PNT2003 (radio equivalent to Lutathera) and upcoming PDUFA for MK-6240, a tau-targeted PET diagnostic slated for August.
• Continued focus on commercial execution in oncology, neurology, and cardiology drove solid volume growth across core products.
• The CEO search advances with strong internal alignment to maintain disciplined capital allocation and long-term pipeline prioritization.